Table 3.
Current utility and future perspectives of PSMA-ligands imaging and 18F-FDG PET/CT in the different subtypes of RCC (−, +, + + for low, intermediate and high utility of the imaging, respectively; values between brackets represent future perspectives)
| Hysthotype | PSMA-ligands Imaging | 18F-FDG PET/CT | |||||
|---|---|---|---|---|---|---|---|
| Staging | Restaging | Therapy Response assessment | RLT | Staging | Restaging | Therapy Response assessment | |
| ccRCC | + + | + + + | + ( +) | (+ +) | + | + | + |
| chrRCC | + | + + | (+ +) | (+) | − | − | − |
| pRCC | − | − | − | − | + + | + + | + + |
18F-FDG 18F-Fluorodeoxyglucose, ccRCC clear cell Renal Cell Carcinoma, chrRCC chromophobe Renal Cell Carcinoma, PET/CT positron emission tomography/computed tomography, pRCC papillary Renal Cell Carcinoma, PSMA prostate-specific membrane antigen, RLT Radioligand Therapy with radiolabelled PSMA-ligands